$PAYS News

Paysign, Inc. (NASDAQ:PAYS) Meets Key CAN SLIM Criteria with Strong Earnings Growth and Zero Debt

Paysign, Inc. (PAYS) Presents at 20th Annual Barrington Research Virtual Spring Investment Conference - Slideshow

Why Paysign (PAYS) Is Down 13.7% After Patient Affordability Revenue Surpasses Plasma Business – And What's Next

PaySign, Inc. Q1 2026 Earnings Call Summary

Paysign (NASDAQ:PAYS) Checks All the CAN SLIM Boxes for Explosive Growth

Paysign, Inc. (PAYS) Q1 2026 Earnings Call Transcript

PaySign Inc (PAYS) Q1 2026 Earnings Call Highlights: Surging Revenue and Strategic Growth ...

Paysign Q1 Earnings Call Highlights

Paysign’s Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026

PaySign Q1 2026 Earnings Call: Complete Transcript

PaySign Affirms FY2026 GAAP EPS Guidance of $0.21-$0.26 vs $0.24 Est; Affirms FY2026 Sales Guidance of $106.500M-$110.500M vs $107.632M Est

PaySign Sees Q2 GAAP EPS $0.06-$0.07 vs $0.06 Est; Sees Sales $26.200M-$26.700M vs $26.595M Est

PaySign Q1 EPS $0.09 Beats $0.07 Estimate, Sales $28.038M Beat $27.008M Estimate

Paysign to Host First Quarter 2026 Earnings Call

Paysign: The Market Is Finally Repricing A Pharma Margin Story

Paysign Is On A Roll

Here's How Much $100 Invested In PaySign 10 Years Ago Would Be Worth Today

Should You Be Adding Paysign (NASDAQ:PAYS) To Your Watchlist Today?

PaySign shares are trading higher after the company reported better-than-expected Q4 sales results and issued Q1, FY26 financial guidance above estimates. Also, Lake Street raised its price target on the stock from $10 to $11.

PaySign shares are trading higher after the company reported better-than-expected Q4 sales results and issued Q1, FY26 financial guidance above estimates. Also, Lake Street raised its price target on the stock from $10 to $11.